Skip to content

Application of ?-3 immunonutrition guided by Prognostic Nutrition Index (PNI) during referral in post-gastrectomy patients: a randomized controlled trial

Application of ?-3 immunonutrition guided by Prognostic Nutrition Index (PNI) during referral in post-gastrectomy patients: a randomized controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600125713
Enrollment
Unknown
Registered
2026-05-29
Start date
2026-05-30
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric Adenocarcinoma

Interventions

Control group:Fat Emulsion,Amino Acids(17) and Glucose(11%) Injection
Experimental group:Omega-3 Acid Triglycerides(2%) Medium and Long Chain Fat Emulsion/Amino Acids(16)/ Glucose(36%) Injection

Sponsors

Chengdu Sixth People'S Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Age >= 18 years old, = 3, and it is expected to continue receiving parenteral nutrition for at least 7 days; 6. The patient or family member signs an informed consent form.

Exclusion criteria

Exclusion criteria: 1.Allergic to omega-3 triglycerides or other drug ingredients used in research (such as egg or soy protein, peanut protein, or other ingredients in prescriptions); 2.There are contraindications to studying drugs; 3.Have used products containing omega-3 fish oil or omega-3 triglycerides within 7 days before entering the Sixth People's Hospital of Chengdu; 4.There are general contraindications for intravenous infusion during the screening period; 5.Pregnant or lactating women; 6.Patients with blood system diseases such as leukemia; 7.Patients with mental disorders or inability to cooperate with treatment and follow-up; 8.Expected survival period<3 months; 9.Researchers believe that patients with any other factors that are not suitable for participating in this trial.

Design outcomes

Primary

MeasureTime frame
length of hospital stay;

Secondary

MeasureTime frame
adverse event;Nutritional indicators (prealbumin, albumin);CRP?IL-6;Healing time of anastomotic fistula;Immune indicators (lymphocytes);The incidence of hospital acquired infections during hospitalization;Prognostic nutritional index;Liver function: AST, ALT, TBIL;Incidence of new complications during hospitalization;30 day readmission rate;

Countries

China

Contacts

Public ContactYuan bo

Chengdu Sixth People'S Hospital

cdlyyboyuan@163.com+86 28 8158 5382

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jun 11, 2026